Good morning :)
Place Order
Add to Watchlist
Home
Portfolio
Search
GoldGold
More

ZIM Laboratories Ltd

ZIMLAB

ZIM Laboratories Ltd

ZIMLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹554 cr, stock is ranked 1,789
High RiskStock is 3.20x as volatile as Nifty
113.810.14% (+0.16)
113.810.14% (+0.16)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹554 cr, stock is ranked 1,789
High RiskStock is 3.20x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹554 cr, stock is ranked 1,789
High RiskStock is 3.20x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
31.002.32—
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.276.550.51%

Forecast & Ratings

Detailed Forecast 
—
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

ZIM Laboratories Limited is a pharmaceutical company. The Company develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments.

Peers

Compare with peers 
Compare with Peers

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Price Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Revenue Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Earnings Per Share Forecast

Hmm, looks like data is unavailable here. Please come back after some time

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Lower than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 2%, vs industry avg of 9.03%

Decreasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 0.15% to 0.1%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 2.36%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue272.42239.86282.09337.42282.26309.60337.83404.94372.60386.87
Raw Materialssubtract156.17118.55141.79159.63149.54159.74170.02182.37185.49337.27
Power & Fuel Costsubtract6.405.355.757.197.477.049.1411.0913.47
Employee Costsubtract30.7033.0040.8048.2635.3535.7640.0749.3253.34
Selling & Administrative Expensessubtract28.4836.6442.2167.1040.7243.0653.7954.0249.83
Operating & Other expensessubtract22.909.987.4711.1622.0527.0819.4349.7323.96
Depreciation/Amortizationsubtract8.769.029.7911.4214.4115.7916.0317.4715.9516.88
Interest & Other Itemssubtract13.659.829.3410.5912.6510.908.315.586.928.06
Taxes & Other Itemssubtract0.26-1.095.826.72-3.222.916.4910.926.396.77
EPS0.120.430.440.350.080.170.331.003.543.67
DPS0.060.060.060.060.000.000.000.000.000.00
Payout ratio0.470.130.130.160.000.000.000.000.000.00
See Costs

EPS and DPS in ₹. Other numbers except Payout Ratio in ₹ cr

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2019

Annual Report Unavailable

Investor Presentation

Feb 15PDF
Dec 4PDF
FY 2020

Annual report

PDF
FY 2021

Annual report

PDF
FY 2022

Annual report

PDF
FY 2023

Annual report

PDF

Investor Presentation

May 19PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 14PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Valuation

Technical

Forecast

ScreenerCompare valuation on Screener

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
ZIM Laboratories Ltd32.152.32—
Sun Pharmaceutical Industries Ltd45.346.470.75%
Cipla Ltd31.214.800.82%
Torrent Pharmaceuticals Ltd65.3815.800.88%

Price Comparison

Compare ZIMLAB with any stock or ETF
Compare ZIMLAB with any stock or ETF
ZIMLAB
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding33.26%0.00%0.10%0.00%66.63%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.06%0.00%0.00%0.01%0.00%0.00%

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ZIMLAB has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 19, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Sep 19, 2019

Cash Dividend

Ex DateEx DateSep 3, 2018

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Sep 3, 2018

News & Opinions
Corporate
Zim Laboratories to conduct board meeting

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 9 November 2024Powered by Capital Market - Live

3 days agoCapital Market - Live

Zim Laboratories consolidated net profit rises 291.30% in the June 2024 quarter

3 months agoBusiness Standard
Earnings
Zim Laboratories consolidated net profit rises 291.30% in the June 2024 quarter

Net profit of Zim Laboratories rose 291.30% to Rs 0.90 crore in the quarter ended June 2024 as against Rs 0.23 crore during the previous quarter ended June 2023. Sales rose 21.32% to Rs 81.82 crore in the quarter ended June 2024 as against Rs 67.44 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales81.8267.44 21 OPM %9.837.16 - PBDT6.184.21 47 PBT1.230.19 547 NP0.900.23 291 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Zim Laboratories to conduct board meeting

Zim Laboratories will hold a meeting of the Board of Directors of the Company on 3 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live

Zim Laboratories consolidated net profit rises 62.16% in the December 2022 quarter

1 year agoBusiness Standard

Sintex Plastics Technology Ltd leads losers in ‘B’ group

1 year agoBusiness Standard

Triveni Turbine, 2 others to trade ex-buyback today; Precision Wires India, Zim Labs to go ex-bonus

1 year agoBusiness Today

Pharma stock is 186% above 52-week-low, record date fixed for 2:1 bonus shares

1 year agoLivemint
ZIM Laboratories Makes D-Street Debut, Gets Listed On National Stock Exchange | #Shorts
1 year agoCNBC-TV18

Multibagger pharma stock declares 2:1 bonus shares, net profit jumps 182% in Q2

1 year agoLivemint